Addex Therapeutics Ltd. announced that it has terminated the Phase 2b/3 study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow recruitment of patients. This has been attributed to the consequences of COVID-19 related patient concerns about participation in clinical studies as well as staffing shortages and turnover within study sites.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.07 CHF | -5.15% | -1.41% | +52.17% |
May. 08 | Addex to Present at BioEURquity Europe 2024 | DJ |
Apr. 30 | European Equities Traded in the US as American Depositary Receipts Decline | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.17% | 10.43M | |
+29.29% | 48.16B | |
-0.71% | 41.73B | |
+43.85% | 41.03B | |
-5.31% | 28.77B | |
+10.60% | 25.59B | |
-21.70% | 18.96B | |
+8.11% | 12.92B | |
+26.74% | 12.03B | |
-3.13% | 11.77B |
- Stock Market
- Equities
- ADXN Stock
- News Addex Therapeutics Ltd
- Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson's Disease due to Slow Recruitment Rate